Campbell’s earnings beat by $0.06, revenue fell short of estimates

Campbell's (CPB) reported fourth-quarter EPS of $0.62, exceeding analyst estimates of $0.56, though revenue of $2.32 billion narrowly missed the $2.33 billion consensus. Critically, the company's FY2026 EPS guidance range of $2.40-$2.55 came in below the $2.61 analyst consensus, signaling a challenging forward outlook. This guidance miss, alongside 16 recent negative EPS revisions and the stock's significant year-over-year decline of nearly 40%, likely outweighs the modest Q4 EPS beat for investors.

Analysis

Campbell's (CPB) reported a mixed fourth quarter, with earnings per share of $0.62 surpassing the analyst estimate of $0.56, while revenue of $2.32 billion narrowly missed the consensus of $2.33 billion. The more critical takeaway for investors is the company's forward-looking guidance. Management's forecast for FY2026 EPS in the range of $2.40-$2.55 falls short of the $2.61 analyst consensus, signaling anticipated headwinds and a weaker earnings outlook. This disappointing guidance is compounded by a clear trend of deteriorating analyst sentiment, evidenced by 16 negative EPS revisions versus zero positive revisions in the past 90 days. The soft guidance and negative revisions provide context for the stock's recent poor performance, which has seen a decline of 8.76% in the last three months and a significant 39.08% drop over the last twelve months. The modest EPS beat is therefore unlikely to offset the concerns raised by the weak revenue figure and, more importantly, the sub-consensus forward guidance.

Key Decisions for Investors

• Investors should prioritize the weak FY2026 EPS guidance over the Q4 EPS beat, as the forward-looking shortfall is a more significant indicator of future performance and valuation.
• Given the stock's 39.08% year-over-year decline and the 16 recent negative analyst revisions, this report confirms an existing bearish trend, warranting caution for those considering initiating a long position.
• The combination of a revenue miss and sub-consensus guidance suggests that fundamental challenges persist, and investors might consider waiting for signs of a strategic turnaround before increasing exposure to CPB.